Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myokardia Inc    MYOK

MYOKARDIA INC (MYOK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
38.4(c) 37.1(c) 37.05(c) 39.25(c) 37.2(c) Last
200 860 229 730 407 365 338 649 305 913 Volume
+0.52% -3.39% -0.13% +5.94% -5.22% Change
More quotes
Financials ($)
Sales 2017 23,0 M
EBIT 2017 -27,8 M
Net income 2017 -54,8 M
Finance 2017 207 M
Yield 2017 -
Sales 2018 22,4 M
EBIT 2018 -37,2 M
Net income 2018 -78,5 M
Finance 2018 122 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 48,8x
EV / Sales2018 53,9x
Capitalization 1 330 M
More Financials
Company
MyoKardia, Inc. is a biopharmaceutical company.It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.The company focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result... 
More about the company
Surperformance© ratings of Myokardia Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYOKARDIA INC
11/17 MYOKARDIA : Preclinical Studies with MyoKardia's Mavacamten Demonstrate Evidence..
11/16 MYOKARDIA : Presents Data from Study of Machine Learning Algorithm Intended to I..
11/15 MYOKARDIA : Presents Data from Study of Machine Learning Algorithm Intended to I..
11/15 MYOKARDIA : Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Ev..
11/14 MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to ..
11/03 MYOKARDIA : Management's Discussion and Analysis of Financial Condition and Resu..
11/03 MYOKARDIA : Announces Presentations at 2017 American Heart Association Scientifi..
11/02 MYOKARDIA : reports 3Q loss
11/02 MYOKARDIA INC : Results of Operations and Financial Condition, Financial Stateme..
11/02 MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progre..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/17 MyoKardia (MYOK) Presents At Stifel 2017 Healthcare Conference - Slideshow
11/04 Stocks to watch next week
11/02 MyoKardia's (MYOK) CEO Tassos Gianakakos on Q3 2017 Results - Earnings Call T..
11/02 MyoKardia misses by $0.01, misses on revenue
11/01 Notable earnings after Thursday?s close
Chart MYOKARDIA INC
Duration : Period :
Myokardia Inc Technical Analysis Chart | MYOK | US62857M1053 | 4-Traders
Technical analysis trends MYOKARDIA INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 56,6 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
June Lee Chief Operating Officer
Jake Bauer Chief Financial Officer
Marc Semigran Chief Medical Officer
Michael P. Graziano Vice President-Research Biology
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA INC187.26%1 330
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805